articleTop 1% cited
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Journal of Clinical Oncology · 2007 · Vol. 25(12) · pp. 1539–1544
Bruce J. Giantonio✉(Dana-Farber Cancer Institute)Paul J. Catalano(Thomas Jefferson University)Neal J. Meropol(University of Pennsylvania)Peter J. O’Dwyer(Thomas Jefferson University)Edith P. Mitchell(Mount Sinai Medical Center)Steven R. Alberts(Thomas Jefferson University)Michael Schwartz(Mount Sinai Medical Center)Al B. Benson(Northwestern University)
Abstract
The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal.
Colorectal Cancer Treatments and StudiesCancer Treatment and PharmacologyHepatocellular Carcinoma Treatment and PrognosisBevacizumabOxaliplatinMedicineColorectal cancerIrinotecanFluorouracilInternal medicineChemotherapyOncologyHazard ratio
MeSH terms
BevacizumabOxaliplatinAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsLeucovorinDose-Response Relationship, DrugDrug Administration ScheduleFemaleFluorouracilFollow-Up StudiesHumansLiver Neoplasms
Citations
2,267
FWCI
86.61
field-weighted impact
References
24
Percentile
100%
vs. same field & year
Citations per year
Cited by
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Journal of Clinical Oncology · 2008 · 2,958 citations
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Cancer Cell · 2014 · 1,503 citations
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
Annals of Oncology · 2012 · 1,518 citations
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
The Lancet Oncology · 2014 · 1,720 citations
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Annals of Oncology · 2016 · 3,389 citations
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2014 · 1,183 citations
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2022 · 1,496 citations
References
Discrete sequential boundaries for clinical trials
Biometrika · 1983 · 1,735 citations
Cancer Statistics, 2004
CA A Cancer Journal for Clinicians · 2004 · 4,003 citations
A Multiple Testing Procedure for Clinical Trials
Biometrics · 1979 · 3,326 citations
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
Journal of Clinical Oncology · 2000 · 3,810 citations
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2003 · 2,265 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
New England Journal of Medicine · 2004 · 10,930 citations
Regression Models and Life-Tables
Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1972 · 38,926 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.